16.06.2017
- US biotechnology group Genentech, part of Roche, is handing back rights to NewLink Genetics’ IDO inhibitor GDC-0919 (navoximod), an investigational cancer treatment. Genentech...
21.04.2015
- ChemoCentryx, Inc, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, has begun enrolling patients with non-resectable...
